BIOTRON LIMITED — Capital/Financing Update 2025

Oct 14, 2025

Appendix 3B - Proposed issue of securities

==> picture [21 x 22] intentionally omitted <==

Announcement Summary

Entity name

BIOTRON LIMITED

Announcement Type

New announcement

Date of this announcement

15/10/2025

The Proposed issue is:

A standard pro rata issue (including non-renounceable or renounceable)

Total number of +securities proposed to be issued for a standard pro rata issue (including non-renounceable or renounceable)

enounceable)
		Maximum Number of
ASX +security code	+Security description	+securities to be issued
New class-code to be	Options (to be listed)	254,388,787
confirmed
BIT	ORDINARY FULLY PAID	508,777,573

Ex date

20/11/2025

+Record date

21/11/2025

Offer closing date

12/12/2025

Issue date

19/12/2025

Refer to next page for full details of the announcement

Appendix 3B - Proposed issue of securities

1 / 8

Appendix 3B - Proposed issue of securities

==> picture [21 x 22] intentionally omitted <==

Part 1 - Entity and announcement details

1.1 Name of +Entity

BIOTRON LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ABN

Registration Number

60086399144

1.3 ASX issuer code

BIT

1.4 The announcement is

New announcement

1.5 Date of this announcement

15/10/2025

1.6 The Proposed issue is:

A standard +pro rata issue (non-renounceable or renounceable)

1.6a The proposed standard +pro rata issue is:

• Non-renounceable

Appendix 3B - Proposed issue of securities

2 / 8

Appendix 3B - Proposed issue of securities

==> picture [21 x 22] intentionally omitted <==

Part 3 - Details of proposed entitlement offer issue

Part 3A - Conditions

3A.1 Do any external approvals need to be obtained or other conditions satisfied before the entitlement offer can proceed on an unconditional basis? Yes 3A.1a Conditions Approval/Condition Date for determination Is the date estimated or ** Approval actual? received/condition met? +Security holder approval 17/11/2025 Actual Comments See announcement dated 15 October 2025

Part 3B - Offer details

+Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued

ASX +security code and description BIT : ORDINARY FULLY PAID

Is the proposed security a 'New Will the proposed issue of this If the entity has quoted company class' (+securities in a class that is +security include an offer of options, do the terms entitle option not yet quoted or recorded by ASX) attaching +securities? holders to participate on exercise? or an 'Existing class' (additional Yes No securities in a class that is already quoted or recorded by ASX)? Existing class

Details of +securities proposed to be issued

ASX +security code and description

BIT : ORDINARY FULLY PAID

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is foreign company and +securities do not have +CDIs issued over them)

Appendix 3B - Proposed issue of securities

3 / 8

Appendix 3B - Proposed issue of securities

==> picture [21 x 22] intentionally omitted <==

Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)	Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)
The quantity of additional +securities	For a given quantity of +securities
to be issued	held
1	3
What will be done with fractional	Maximum number of +securities
entitlements?	proposed to be issued (subject to
	rounding)
Fractions rounded up to the next	508,777,573
whole number
Offer price details for retail security holders
In what currency will the offer be	What is the offer price per +security
made?	for the retail offer?
AUD - Australian Dollar	AUD 0.00300

Oversubscription & Scale back details

Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)? Yes

Describe the limits on over-subscription

The limit available under the rights issue

Will a scale back be applied if the offer is over-subscribed? Yes Describe the scale back arrangements

In the event that the offer is over subscribed, applicants will be scaled back in accordance with the allocation policy set out in the in the offer prsospectus

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Yes

Attaching +Security

Is the proposed attaching security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional +securities in a class that is already quoted or recorded by ASX)? New class

Attaching +Security - New class (+securities in a class that is not yet quoted or recorded by ASX)

Details of attaching +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is

Appendix 3B - Proposed issue of securities

4 / 8

Appendix 3B - Proposed issue of securities

==> picture [21 x 22] intentionally omitted <==

foreign company and +securities do not have +CDIs issued over them)

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1? No

Will the entity be seeking quotation of the 'new' class of +securities on ASX? Yes

ASX +security code +Security description New class-code to be confirmed Options (to be listed)

+Security type

Options

Offer ratio (ratio of attaching securities at which the new +securities will be issued)

The quantity of attaching +securities to be issued For a given quantity of the new +securities issued 1 2 What will be done with fractional entitlements? Maximum number of +securities proposed to be issued (subject to rounding) Fractions rounded down to the nearest whole number or fractions disregarded 254,388,787

Offer price details for retail security holders

In what currency will the offer be made? What is the offer price per +security for the retail offer? AUD 0.00000

AUD - Australian Dollar

Oversubscription & Scale back details

Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)? Yes

Describe the limits on over-subscription

The limit available under the rights issue

Will a scale back be applied if the offer is over-subscribed? Yes

Describe the scale back arrangements

In the event that the offer is over subscribed, applicants will be scaled back in accordance with the allocation policy set out in the in the offer prsospectus

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Options details

+Security currency

AUD - Australian Dollar

Appendix 3B - Proposed issue of securities

5 / 8

Appendix 3B - Proposed issue of securities

==> picture [21 x 22] intentionally omitted <==

Exercise price Expiry date AUD 0.0200 24/11/2027

Details of the type of +security that will be issued if the option is exercised

BIT : ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

If all options are exercised 254,388,787 ordinary shares will be issued

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

The prospectus will be released to the ASX on 17 November 2025

Part 3C - Timetable

3C.1 +Record date

21/11/2025

3C.2 Ex date

20/11/2025

3C.4 Record date

21/11/2025

3C.5 Date on which offer documents will be sent to +security holders entitled to participate in the +pro rata issue 26/11/2025

3C.6 Offer closing date

12/12/2025

3C.7 Last day to extend the offer closing date

9/12/2025

3C.9 Trading in new +securities commences on a deferred settlement basis

15/12/2025

3C.11 +Issue date and last day for entity to announce results of +pro rata issue

19/12/2025

3C.12 Date trading starts on a normal T+2 basis

22/12/2025

3C.13 First settlement date of trades conducted on a +deferred settlement basis and on a normal T+2 basis

24/12/2025

Appendix 3B - Proposed issue of securities

6 / 8

Appendix 3B - Proposed issue of securities

==> picture [21 x 22] intentionally omitted <==

Part 3E - Fees and expenses

3E.1 Will there be a lead manager or broker to the proposed offer? Yes 3E.1a Who is the lead manager/broker? Peak Asset Management 3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker? Cash Commission of 6%; 3E.2 Is the proposed offer to be underwritten? Yes 3E.2a Who are the underwriter(s)? Peak Asset Management 3E.2b What is the extent of the underwriting (ie the amount or proportion of the offer that is underwritten)? Up to the maximum amount of the rights issue 3E.2c What fees, commissions or other consideration are payable to them for acting as underwriter(s)? No 3E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated The acquisition of Sedarex Limited is not approved by shareholders. 3E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer? No 3E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission? No 3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer Nil Part 3F - Further Information 3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue Progress the Company's Hepatitis B virus drug and for working capital 3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining entitlements to the issue? No 3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful? No 3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed issue All countries other than Australia and New Zealand 3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities No 3F.6 URL on the entity's website where investors can download information about the proposed issue www.biotron.com.au

Appendix 3B - Proposed issue of securities

7 / 8

Appendix 3B - Proposed issue of securities

==> picture [21 x 22] intentionally omitted <==

3F.7 Any other information the entity wishes to provide about the proposed issue

No

3F.8 Will the offer of rights under the rights issue be made under a +disclosure document or product disclosure statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)? Yes

3F.9 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: The publication of a +disclosure document or +PDS for the +securities proposed to be issued

Appendix 3B - Proposed issue of securities

8 / 8